Katifelis, H.; Zerva, S.-E.; Bamias, A.; Karamouzis, M.V.; Stravodimos, K.; Sechi, L.A.; Lampropoulou, D.-I.; Pliakou, E.; Gazouli, M.
Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma. Cancers 2026, 18, 716.
https://doi.org/10.3390/cancers18040716
AMA Style
Katifelis H, Zerva S-E, Bamias A, Karamouzis MV, Stravodimos K, Sechi LA, Lampropoulou D-I, Pliakou E, Gazouli M.
Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma. Cancers. 2026; 18(4):716.
https://doi.org/10.3390/cancers18040716
Chicago/Turabian Style
Katifelis, Hector, Styliani-Evangelia Zerva, Aristotelis Bamias, Michalis V. Karamouzis, Konstantinos Stravodimos, Leonardo A. Sechi, Dimitra-Ioanna Lampropoulou, Evangelia Pliakou, and Maria Gazouli.
2026. "Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma" Cancers 18, no. 4: 716.
https://doi.org/10.3390/cancers18040716
APA Style
Katifelis, H., Zerva, S.-E., Bamias, A., Karamouzis, M. V., Stravodimos, K., Sechi, L. A., Lampropoulou, D.-I., Pliakou, E., & Gazouli, M.
(2026). Circulating ERVFRD-1 and MFSD2A Are Associated with Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma. Cancers, 18(4), 716.
https://doi.org/10.3390/cancers18040716
